Healthcare · Drug Manufacturers - Specialty & Generic
Hanall Biopharma Co. Ltd.
009420KRX₩51,100₩0 (0.00%)Market closed
KRW
KRW
% of revenue
Statements
5 periods| Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | |||||
| Sales | 155.18B | 138.94B | 134.91B | 110.00B | 101.59B |
| Cost of Goods Sold | 74.33B | 65.64B | 59.74B | 48.02B | 41.26B |
| Gross Profit | 80.86B | 73.31B | 75.17B | 61.97B | 60.33B |
| Gross Margin | 52.1% | 52.8% | 55.7% | 56.3% | 59.4% |
| Operating | |||||
| SG&A | 38.27B | 29.95B | 25.69B | 23.24B | 20.52B |
| R&D | 19.31B | 19.99B | 23.94B | 16.50B | 10.46B |
| Other Expenses | 750.0M | 634.4M | 852.7M | 741.0M | 685.6M |
| Operating Income | −915.8M | 230.5M | 2.21B | 1.51B | 10.10B |
| Operating Margin | -0.6% | 0.2% | 1.6% | 1.4% | 9.9% |
| EBITDA | 2.84B | 3.35B | 6.11B | 5.36B | 12.98B |
| EBITDA Margin | 1.8% | 2.4% | 4.5% | 4.9% | 12.8% |
| EBIT | −6.04B | −112.2M | 3.27B | 1.95B | 8.73B |
| Non-Operating | |||||
| Other Income | 263.1M | 490.3M | 1.23B | 1.43B | 719.8M |
| Other Expenses | 142.5M | 71.0M | 63.9M | 21.9M | 25.5M |
| Other Income/Expense | — | — | — | — | — |
| Net Income | |||||
| Income Before Tax | −6.18B | −183.2M | 3.20B | 1.93B | 8.70B |
| Pre-Tax Margin | -4.0% | -0.1% | 2.4% | 1.8% | 8.6% |
| Income Tax Expense | −620.7M | 1.62B | −306.1M | 1.68B | −194.0M |
| Net Income | −5.56B | −1.80B | 3.51B | 251.5M | 8.90B |
| Net Margin | -3.6% | -1.3% | 2.6% | 0.2% | 8.8% |